NASDAQ · GTBP
GT Biopharma, Inc.
Healthcare · Biotechnology
$6.16
Up+$0.21 (+3.41%)
Updated Oct 6, 2026, 9:42 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.84M
- P/E ratio
- -0.27
- Dividend yield
- 0.00%
- 52-week range
- $0.26 – $11.98
- Volume
- 38.73K
- Avg. volume
- 2.07M
Price performance · GTBP
GTBP price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
GTBP closed at $6.16 after 20 trading sessions, up 17.57% for the selected period.
- Last close
- $6.16
- Period change
- +17.57%
- Period low
- $5.24
- Period high
- $11.63
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $6.13 | $6.68 | $6.12 | $6.16 | 38.73K |
| Oct 2, 2026 | $6.36 | $6.51 | $6.00 | $6.10 | 62.62K |
| Oct 1, 2026 | $6.34 | $6.46 | $6.00 | $6.20 | 39K |
| Sep 30, 2026 | $6.85 | $7.0166 | $6.47 | $6.47 | 29.76K |
| Sep 29, 2026 | $7.08 | $7.10 | $6.7101 | $6.875 | 34.97K |
| Sep 28, 2026 | $7.00 | $7.25 | $6.79 | $6.80 | 36.98K |
| Sep 25, 2026 | $6.79 | $7.24 | $6.59 | $6.89 | 79.84K |
| Sep 24, 2026 | $7.01 | $7.10 | $6.59 | $6.83 | 28.22K |
| Sep 23, 2026 | $7.08 | $7.2751 | $6.825 | $7.10 | 53.73K |
| Sep 22, 2026 | $7.12 | $7.20 | $6.3501 | $7.18 | 74.67K |
| Sep 21, 2026 | $7.16 | $7.82 | $6.8801 | $7.18 | 57.71K |
| Sep 18, 2026 | $7.52 | $7.52 | $7.11 | $7.16 | 37.47K |
| Sep 17, 2026 | $7.80 | $7.80 | $6.3301 | $7.49 | 110.66K |
| Sep 16, 2026 | $9.04 | $9.04 | $7.31 | $7.81 | 107.92K |
| Sep 15, 2026 | $10.48 | $10.48 | $8.13 | $9.00 | 335.29K |
| Sep 14, 2026 | $8.69 | $11.98 | $8.65 | $11.63 | 524.3K |
| Sep 11, 2026 | $6.59 | $8.8199 | $6.59 | $8.61 | 544.28K |
| Sep 10, 2026 | $6.13 | $6.74 | $5.50 | $6.18 | 161.35K |
| Sep 9, 2026 | $5.47 | $6.24 | $5.12 | $5.98 | 120.05K |
| Sep 8, 2026 | $5.62 | $5.95 | $4.9101 | $5.2395 | 88.5K |
Latest GTBP news
The latest Smart Investors Daily articles mentioning GTBP.
Stock researchMarket Activity · Sentiment
Company
Market Activity
Research & News

